CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates... Read More

CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock from The Nasdaq Stock... Read More

CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25.... Read More

TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical models $12 million financing completed, including non-dilutive $2 million tranche and $10 million reduction in liabilities associated with existing ex-US royalty financing CHESTERBROOK, Pa., Aug. 08,... Read More

Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing CHESTERBROOK, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development... Read More

TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in validated preclinical models TRV045 did not show a statistically significant effect in preliminary preclinical model of epileptogenesis, but... Read More

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc . (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... Read More

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for... Read More

CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“ Trevena ” or the “ Company ”) ( Nasdaq: TRVN ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants... Read More

CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“ Trevena ” or the “ Company ”) ( Nasdaq: TRVN ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu... Read More

Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P 1 receptor without associated lymphopenia CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of... Read More

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take... Read More

CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the p R ospective, case-controlled E valuation of o LI ceridine for moderate or s EVE re pain in patients with acute burn injuries... Read More

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in... Read More

CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a... Read More

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for... Read More

Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates VOLITION data to be presented at the American Society of Anesthesiologists Meeting October 13-17, 2023 Company will also participate in the BIO Investor Forum October 17-18, 2023 CHESTERBROOK, Pa., Oct.... Read More

TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant Evidence of CNS Activity of TRV045 on Day 4 as Measured by EEG Power Spectral Analysis No SAEs and No Study Drug-Related Discontinuations were reported; Full Safety and Tolerability Data Expected in early 4Q 2023 Company to Hold... Read More

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate... Read More

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023 New respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Company previously... Read More

CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023. “We are pleased to welcome Mark to Trevena’s Board of Directors,”... Read More

OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982) New respiratory data from VOLITION ~200 patient real-world outcomes study using continuous respiratory monitoring expected 3Q 2023 CHESTERBROOK, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc.... Read More

$3 million milestone payment for Chinese approval of OLINVYK ® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBROOK, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous... Read More

CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) informing Trevena that it has regained compliance with the... Read More

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from R-Bridge upon first commercial sale of OLINVYK in China TRV045 topline data expected in 3Q 2023 for two proof-of-concept studies supporting continued development for potential use in epilepsy and chronic pain... Read More

CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023. The Company will host a conference call... Read More

Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on first commercial sale in China, based on ex-US Royalty-Based Financing with R-Bridge Healthcare Fund, an affiliate of CBC Group CHESTERBROOK, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:... Read More

CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences. JMP Securities Life Sciences Conference Date: May 15 th to May 16 th , 2023 Location: New York, NY... Read More

OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS patients at Wake Forest Baptist Health OLINVYK-treated patients had a 52.2% GI complete responder rate, defined as no vomiting and no antiemetic use throughout the post-operative period, based on... Read More

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to advance as a potential treatment for epilepsy, diabetic neuropathic pain and other CNS disorders, with two proof-of-concept studies expected to complete enrollment by mid-2023 Cash balance of $38.3 million at year... Read More

CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, prior to the market open on Thursday, March 30, 2023. The Company... Read More

CHESTERBROOK, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. The study will use... Read More

OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results that suggest OLINVYK provides a reduced impact on ventilatory function as compared to IV morphine CHESTERBROOK, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel... Read More

New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS disorders TRV045, a novel S1P receptor modulator, is highly specific for S1PR subtype 1 and reported no lymphopenia in a prior Phase 1 clinical study CHESTERBROOK, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a... Read More

TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced effect on neurocognitive function in humans compared to morphine presented at ACNP Annual Meeting OLINVYK comparison analysis versus other opioid treatments showed reduced gastrointestinal adverse effects presented at... Read More